Kailera Therapeutics, Inc. (KLRA) shareholders
Close on Nov 17, 2026Market cap $1.58BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BCPE Perseus Investor, LP | 26,255,581 | 20.27% | 13D (active) | Apr 16, 2026 |
| BCLS Fund IV Investments, L.P. | 22,583,268 | 17.43% | 13D (active) | Apr 16, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 11,511,853 | 8.90% | 13G (passive) | Jun 30, 2026 |
| RTW Investments, LP Joint filing with Roderick Wong (8.30%) | 10,776,820 | 8.30% | 13G (passive) | Jun 30, 2026 |
| CPP Investment Board Private Holdings (4) Inc. Joint filing with Canada Pension Plan Investment Board (5.60%) | 7,304,688 | 5.60% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KLRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bain Capital Investors LLC | 26,255,581 | 20.25% | $578.41M | New | 12.01% |
| Bain Capital Life Sciences Investors, LLC | 22,583,268 | 17.42% | $497.51M | New | 29.58% |
| Rtw Investments, LP | 10,776,820 | 8.31% | $237.41M | New | 2.03% |
| Canada Pension Plan Investment Board | 7,304,688 | 5.63% | $160.92M | New | 0.09% |
| Atlas Venture Life Science Advisors, LLC | 5,171,282 | 3.99% | $113.92M | New | 12.93% |
| FMR LLC | 3,970,865 | 3.06% | $87.48M | New | 0.00% |
| BlackRock, Inc. | 3,928,604 | 3.03% | $86.55M | New | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,534,410 | 2.73% | $77.86M | New | 0.01% |
| Citadel Advisors LLC | 3,240,787 | 2.50% | $71.39M | New | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 3,208,286 | 2.47% | $70.68M | New | 0.10% |
| Wellington Management Group Llp | 2,919,110 | 2.25% | $64.31M | New | 0.01% |
| Royalty Pharma Sub-Manager, LLC | 2,455,357 | 1.89% | $54.09M | New | 22.36% |
| Siren, L.L.C. | 2,214,286 | 1.71% | $48.78M | New | 0.99% |
| Vanguard Capital Management LLC | 1,693,958 | 1.31% | $37.32M | New | 0.00% |
| Vanguard Portfolio Management LLC | 1,652,507 | 1.27% | $36.40M | New | 0.00% |
| Geode Capital Management, LLC | 1,133,115 | 0.87% | $24.97M | New | 0.00% |
| Frazier Life Sciences Management, L.P. | 1,100,000 | 0.85% | $24.23M | New | 0.53% |
| Farallon Capital Management LLC | 1,100,000 | 0.85% | $24.23M | New | 0.11% |
| Trails Edge Capital Partners, LP | 984,786 | 0.76% | $21.69M | New | 3.44% |
| UBS Group AG | 972,683 | 0.75% | $21.43M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 99 | 116M | 89.6% | 99 / 0 | 0 / 0 | 116M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KLRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 2,191,928 | 1.69% | $37.13M | 0.10% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,180,411 | 0.91% | $26.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,163,223 | 0.90% | $25.63M | 0.03% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 904,283 | 0.70% | $19.92M | 0.17% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 850,042 | 0.66% | $18.73M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 752,900 | 0.58% | $17.27M | 0.02% | May 31, 2026 |
| Columbia Small Cap Growth Fund | 652,308 | 0.50% | $14.96M | 0.41% | May 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 635,206 | 0.49% | $13.99M | 0.14% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 619,399 | 0.48% | $14.21M | 0.27% | May 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 616,720 | 0.48% | $13.59M | 0.76% | Jun 30, 2026 |
| Fidelity Blue Chip Growth Fund | 587,097 | 0.45% | $9.95M | 0.01% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 503,961 | 0.39% | $8.54M | 0.03% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 487,994 | 0.38% | $10.75M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 476,221 | 0.37% | $10.49M | 0.01% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 464,174 | 0.36% | $10.65M | 0.18% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ronald C. Renaud JR | CEO & President, Director | 38,094 | 0.03% | Jun 11, 2026 |
| Nur Nicholson | Chief Technology Officer | – | – | Sep 9, 2026 |
| Kathleen Tregoning | See Remarks | – | – | Jul 8, 2026 |
| Paul D. Burgess | See Remarks | – | – | Apr 20, 2026 |
| Paula Cloghessy | Chief People Officer | – | – | Apr 20, 2026 |
| Jamie Beth Coleman | Chief Commercial Officer | – | – | Apr 20, 2026 |
| Scott Akamine | Chief Legal Officer | – | – | Apr 20, 2026 |
| Scott M. Wasserman | Chief Medical Officer | – | – | Apr 20, 2026 |
| Douglas W. Pagan | Chief Financial Officer | – | – | Apr 20, 2026 |
| Frank Clyburn | Director | – | – | Apr 20, 2026 |
| Christopher Hite | Director | – | – | Apr 20, 2026 |
| John F. Milligan | Director | – | – | Apr 20, 2026 |
| Martin Mackay | Director | – | – | Apr 20, 2026 |
| Adam Koppel | Director, 10% owner | 16,875,000 | 13.02% | Apr 20, 2026 |
| Andrew T. Kaplan | Director, 10% owner | 17,857,143 | 13.77% | Apr 20, 2026 |
| Yuting Liu | Director | – | – | Apr 16, 2026 |
| Roderick Wong | 10% owner | – | – | Apr 22, 2026 |
| Rtw Investments, Lp | 10% owner | 10,776,820 | 8.31% | Apr 22, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | 9,477,720 | 7.31% | Apr 22, 2026 |
| BCLS Fund IV Investments, L.P. | 10% owner | – | – | Apr 20, 2026 |
| Capital Investors Llc Bain | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Life Sciences IV General Partner, LLC | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Fund XIV, L.P. | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital XIV General Partner, LLC | 10% owner | – | – | Apr 20, 2026 |
| BCPE Perseus Investor GP, LLC | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Life Sciences Fund IV, L.P. | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | – | – | Apr 20, 2026 |
| BCPE Perseus Investor, LP | 10% owner | 26,255,581 | 20.25% | Apr 20, 2026 |
| BCLS Fund IV Investments GP, LLC | 10% owner | 21,020,768 | 16.21% | Apr 20, 2026 |
| Stuart Partners, LLC | 10% owner | – | – | Apr 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ronald C. Renaud JR CEO & President, Director | Jun 9, 2026 | Option exercise | +38,094 | $5.25 | $199.99K | 38,094 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Apr 20, 2026 | Conversion | +9,477,719 | – | – | 9,477,719 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Apr 20, 2026 | Conversion | +2,034,133 | – | – | 2,034,133 |
| Rtw Investments, Lp 10% owner | Apr 20, 2026 | Buy | +500,000 | $16.00 | $8.00M | 10,776,820 |
| Rtw Investments, Lp 10% owner | Apr 20, 2026 | Conversion | +10,276,820 | – | – | 10,276,820 |
| Adam Koppel Director, 10% owner | Apr 20, 2026 | Conversion | +16,875,000 | – | – | 16,875,000 |
| Adam Koppel Director, 10% owner | Apr 20, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 22,583,268 |
| Adam Koppel Director, 10% owner | Apr 20, 2026 | Conversion | +4,145,768 | – | – | 21,020,768 |
| Andrew T. Kaplan Director, 10% owner | Apr 20, 2026 | Conversion | +17,857,143 | – | – | 17,857,143 |
| Andrew T. Kaplan Director, 10% owner | Apr 20, 2026 | Buy | +8,398,438 | $16.00 | $134.38M | 26,255,581 |
| BCLS Fund IV Investments GP, LLC 10% owner | Apr 20, 2026 | Conversion | +4,145,768 | – | – | 21,020,768 |
| BCLS Fund IV Investments GP, LLC 10% owner | Apr 20, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 22,583,268 |
| BCLS Fund IV Investments GP, LLC 10% owner | Apr 20, 2026 | Conversion | +16,875,000 | – | – | 16,875,000 |
| BCPE Perseus Investor, LP 10% owner | Apr 20, 2026 | Buy | +8,398,438 | $16.00 | $134.38M | 26,255,581 |
| BCPE Perseus Investor, LP 10% owner | Apr 20, 2026 | Conversion | +17,857,143 | – | – | 17,857,143 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 7 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kailera Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 78,380 shares on Sep 28, 2026 over the last 90 days.
See a number that looks wrong?